Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy

References

• Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. JCO. 1988;6:239–252.
   PubMed Web of Science ®Google Scholar
• Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,833 patients. International Hodgkin’s Disease Collaborative Group. JCO. 1998;16:830–843.
   PubMed Web of Science ®Google Scholar
• Boivin JF, Hutchison GB, Zauber AG, et al. Incidence of second cancers in patients treated for Hodgkin’s disease. J Natl Cancer Inst. 1995;87:732–741.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487–497.
   PubMed Web of Science ®Google Scholar
• Ng AK, Bernardo WP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–2108.
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357:1916–1927.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252–259.
   PubMed Web of Science ®Google Scholar
• Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. JCO. 2007;25:3495–3502.
   PubMed Web of Science ®Google Scholar
• Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. JCO. 2003;21:3601–3608.
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Sasse S, Brockelmann PJ, Goergen H, et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD, 10, and HD11 trials. JCO. 2017;35:1999–2007.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin’s lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89:854–862.
   PubMed Web of Science ®Google Scholar
• Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270–277.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Voss N, Pickels T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;26:5170–5174.
   PubMed Web of Science ®Google Scholar
• Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol. 2002;13:79–83.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;83:1232–1237.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 2006;91:482–489.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood 2016;127:1531–1538.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372:1598–1607.
   PubMed Web of Science ®Google Scholar
• Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. JCO. 2014;32:1188–1194.
   PubMed Web of Science ®Google Scholar
• Andre MP, Girinsky T, Federico M, etet al. Early positron emission tomography response–adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017;35:1786–1794.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958; 53:457–481.
   Web of Science ®Google Scholar
• Koshy M, Rich SE, Mahmood U, et al. Declining use of radiotherapy in stage I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys. 2012;82:619–625.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. JCO. 2015;33:625–633.
   PubMed Web of Science ®Google Scholar
• Parikh RR, Grossbard ML, Harrison LB, et al. Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival. Int J Radiat Oncol Biol Phys. 2015;93:684–693.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2015;2:e492–e502.
   PubMed Web of Science ®Google Scholar
• Kumar A, Burger IA, Zhang Z, et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. Haematologica 2016;101:1237–1243.
   PubMed Web of Science ®Google Scholar